The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Treatment With Once-Weekly Alendronate 70 mg Compared With Once-Weekly Risedronate 35 mg in Women With Postmenopausal Osteoporosis: A Randomized Double-Blind Study
Open accessAbstract
Once-weekly alendronate 70 mg and once-weekly risedronate 35 mg are indicated for the treatment of postmenopausal osteoporosis. These two agents were compared in a 12-month head-to-head trial. Greater gains in BMD and greater reductions in markers of bone turnover were seen with alendronate compared with risedronate with similar tolerability. Introduction: The nitrogen-containing bisphosphonates, alendronate and risedronate, are available in once-weekly (OW) formulations for the treatment of postmenopausal osteoporosis. A 12-month, head-to-head study was performed to compare these agents in the treatment of postmenopausal women with low BMD. Materials and Methods: A total of 1053 patients from 78 U.S. sites were randomized to OW alendronate 70 mg (N = 520) or risedronate 35 mg (N = 533), taken in the morning after fasting. Endpoints included BMD changes over 6 and 12 months at the hip trochanter, total hip, femoral neck, and lumbar spine (LS); percent of patients with predefined levels of change in trochanter and LS BMD at 12 months; and change in biochemical markers of bone turnover at 3, 6, and 12 months. Tolerability was evaluated by adverse experience (AE) reporting. Results: Significantly greater increases in hip trochanter BMD were seen with alendronate (3.4%) than risedronate (2.1%) at 12 months (treatment difference, 1.4%; p < 0.001) as well as 6 months (treatment difference, 1.3%; p < 0.001). Significantly greater gains in BMD were seen with alendronate at all BMD sites measured (12-month difference: total hip, 1.0%; femoral neck, 0.7%; LS, 1.2%). Significant differences were seen as early as 6 months at all sites. A greater percentage of patients had ≥0% (p < 0.001) and ≥3% (p < 0.01) gain in trochanter and spine BMD at 12 months with alendronate than risedronate. Significantly greater (p < 0.001) reductions in all biochemical markers of bone turnover occurred with alendronate compared with risedronate by 3 months. No significant differences were seen between treatment groups in the incidence of upper gastrointestinal AEs or AEs causing discontinuation. Conclusions: In this 12-month, head-to-head trial of alendronate and risedronate, given in accordance with the approved OW regimens for treatment of osteoporosis in postmenopausal women, alendronate produced greater gains in BMD and greater reductions in markers of bone turnover than risedronate. The greater antiresorptive effect of alendronate was seen as early as 3 months, and the tolerability profiles were similar.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Users' guides to the medical literature
Guyatt, G. H. (1993) · JAMA · doi:10.1001/jama.270.17.2096 · Cited by 2,970
Bone density at various sites for prediction of hip fractures
Cummings, S. R., Browner, W., Cummings, S. R., Black, D. M., Nevitt, M. C., Browner, W., Genant, H. K., Cauley, J., Ensrud, K., Scott, J., et al. (1993) · The Lancet · doi:10.1016/0140-6736(93)92555-8 · Cited by 2,446
Reginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580
Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal Women
Bone, H. G., Hosking, D., Devogelaer, J.-P., Tucci, J. R., Emkey, R. D., Tonino, R. P., Rodriguez-Portales, J. A., Downs, R. W., Gupta, J., Santora, A. C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030897 · Cited by 1,347
Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis
Dr. Garnero, P., Sornay-Rendu, E., Chapuy, M.-C., & Delmas, P. D. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650110307 · Cited by 1,001
Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study
Garnero, P., Hausherr, E., Chapuy, M.-C., Marcelli, C., Grandjean, H., Muller, C., Cormier, C., Bréart, G., Meunier, P. J., & Dr. Delmas, P. D. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650111021 · Cited by 989
Fracture Risk Reduction with Alendronate in Women with Osteoporosis: The Fracture Intervention Trial
Black, D. M., Thompson, D. E., Bauer, D. C., Ensrud, K., Musliner, T., Hochberg, M. C., Nevitt, M. C., Suryawanshi, S., & Cummings, S. R. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.11.6953 · Cited by 982
Self-citationSome comments on frequently used multiple endpoint adjustment methods in clinical trials
Sankoh, A. J., Huque, M. F., & Dubey, S. D. (1997) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19971130)16:22<2529::aid-sim692>3.0.co;2-j · Cited by 805
Cummings, S. R., Karpf, D. B., Harris, F., Genant, H. K., Ensrud, K., LaCroix, A. Z., & Black, D. M. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)01124-x · Cited by 752
Mashiba, T., Hirano, T., Turner, C. H., Forwood, M. R., Johnston, C. C., & Burr, D. B. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.4.613 · Cited by 688
IX: Summary of Meta-Analyses of Therapies for Postmenopausal Osteoporosis
Cranney, A., Guyatt, G., Griffith, L., Wells, G., Tugwell, P., Rosen, C., The Osteoporosis Methodology Group, & The Osteoporosis Research Advisory Group (2002) · Endocrine Reviews · doi:10.1210/er.2001-9002 · Cited by 604
Self-citationRelationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate
Eastell, R., Barton, I., Hannon, R., Chines, A., Garnero, P., & Delmas, P. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.6.1051 · Cited by 588
A Solution to the Ecological Inference Problem
Freedman, D. A., Klein, S. P., Ostland, M., Roberts, M. R., & King, G. (1998) · Journal of the American Statistical Association · doi:10.2307/2670067 · Cited by 527
Axial and appendicular bone density predict fractures in older women
Black, D. M., Cummings, S. R., Genant, H. K., Nevitt, M. C., Palermo, L., & Browner, W. (1992) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650070607 · Cited by 510
Hochberg, M. C. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.4.1586 · Cited by 480
Self-citationMeta-Analyses of Therapies for Postmenopausal Osteoporosis
Osteoporosis Methodology Group, & The Osteoporosis Research Advisory Group (2002) · Endocrine Reviews · doi:10.1210/edrv.23.4.0486 · Cited by 471
II. Meta-Analysis of Alendronate for the Treatment of Postmenopausal Women
Cranney, A., Wells, G., Willan, A., Griffith, L., Zytaruk, N., Robinson, V., Black, D., Adachi, J., Shea, B., Tugwell, P., et al. (2002) · Endocrine Reviews · doi:10.1210/er.2001-2002 · Cited by 445
Sarkar, S., Mitlak, B. H., Wong, M., Stock, J. L., Black, D. M., & Harper, K. D. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.1.1 · Cited by 442
Antifracture Efficacy of Antiresorptive Agents Are Related to Changes in Bone Density
Wasnich, R. D. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.1.231 · Cited by 417
Bauer, D. C., Black, D. M., Garnero, P., Hochberg, M., Ott, S., Orloff, J., Thompson, D. E., Ewing, S. K., Delmas, P. D., & for the Fracture Intervention Trial Study Group (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040512 · Cited by 405
Self-citationAlendronate Once-Weekly Study Group, Schnitzer, T., Bone, H. G., Crepaldi, G., Adami, S., McClung, M., Kiel, D., Felsenberg, D., Recker, R. R., Tonino, R. P., et al. (2000) · Aging Clinical and Experimental Research · doi:10.1007/bf03339822 · Cited by 394
Self-citationRadiographic osteoarthritis of the hip and bone mineral density
Nevitt, M. C., Lane, N. E., Scott, J. C., Hochberg, M. C., Pressman, A. R., Genant, H. K., & Cummings, S. R. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380706 · Cited by 362
Self-citationBucher, H. C., Guyatt, G. H., Cook, D. J., Holbrook, A., McAlister, F. A., & for the Evidence-Based Medicine Working Group (1999) · JAMA · doi:10.1001/jama.282.8.771 · Cited by 361
Standing, O. (2002) · Cited by 351
Brown, J. P., Kendler, D. L., McClung, M. R., Emkey, R. D., Adachi, J. D., Bolognese, M. A., Li, Z., Balske, A., & Lindsay, R. (2002) · Calcified Tissue International · doi:10.1007/s00223-002-2011-8 · Cited by 330
Self-citationSchnitzer, T. J., Bone, H. G., Crepaldi, G., Adámi, S., McClung, M. R., Kiel, D. P., Felsenberg, D., Recker, R. R., Tonino, R. P., Roux, C., et al. (2000) · PubMed · Cited by 299
Self-citationDelmas, P. D., & Seeman, E. (2004) · Bone · doi:10.1016/j.bone.2003.12.022 · Cited by 294
Hochberg, M. C., Ross, P. D., Black, D., Cummings, S. R., Genant, H. K., Nevitt, M. C., Barrett-Connor, E., Musliner, T., Thompson, D., & for the Fracture Intervention Trial Research Group (1999) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199906)42:6<1246::aid-anr22>3.0.co;2-u · Cited by 287
Self-citationVI. Meta-Analysis of Calcitonin for the Treatment of Postmenopausal Osteoporosis
Cranney, A., Tugwell, P., Zytaruk, N., Robinson, V., Weaver, B., Shea, B., Wells, G., Adachi, J., Waldegger, L., Guyatt, G., et al. (2002) · Endocrine Reviews · doi:10.1210/er.2001-6002 · Cited by 286
Importance of Precision in Bone Density Measurements
Bonnick, S. L., Johnston, C. C., Kleerekoper, M., Lindsay, R., Miller, P., Sherwood, L., & Siris, E. (2001) · Journal of Clinical Densitometry · doi:10.1385/jcd:4:2:105 · Cited by 277
Self-citationBjarnason, N. H., Sarkar, S., Duong, T., Mitlak, B., Delmas, P. D., & Christiansen, C. (2001) · Osteoporosis International · doi:10.1007/s001980170020 · Cited by 230
Sarkar, S., Reginster, J.-Y., Crans, G. G., Diez-Perez, A., Pinette, K. V., & Delmas, P. D. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0301243 · Cited by 210
Fracture Risk Reduction with Alendronate in Women with Osteoporosis: The Fracture Intervention Trial
Black, D. M. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.11.4118 · Cited by 187
McAlister, F. A., Laupacis, A., Wells, G. A., Sackett, D. L., & for the Evidence-Based Medicine Working Group (1999) · JAMA · doi:10.1001/jama.282.14.1371 · Cited by 177
Marcus, R., Wong, M., Heath, H., & Stock, J. L. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.1.0453 · Cited by 164
A method to assess the proportion of treatment effect explained by a surrogate endpoint
Li, Z., Meredith, M. P., & Hoseyni, M. S. (2001) · Statistics in Medicine · doi:10.1002/sim.984 · Cited by 153
Garnero, P., Dargent‐Molina, P., Hans, D., Schott, A., Bréart, G., Meunier, P. J., & Delmas, P. D. (1998) · Osteoporosis International · doi:10.1007/s001980050100 · Cited by 148
Perspective: Reconsidering the Effects of Antiresorptive Therapies in Reducing Osteoporotic Fracture
Chesnut, C. H., & Rosen, C. J. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.12.2163 · Cited by 146
Self-citationDelmas, P. D., Li, Z., & Cooper, C. C. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0301228 · Cited by 125
Hosking, D. J., Adami, S., Felsenberg, D., Cannata-Andía, J. B., Välimäki, M. J., Benhamou, L., Reginster, J., Yacik, C., Rybak-Feiglin, A., Petruschke, R. A., et al. (2003) · Current Medical Research and Opinion · doi:10.1185/030079903125002009 · Cited by 96
Self-citationGarnero, P., Mulleman, D., Munoz, F., Sornay‐Rendu, E., & Delmas, P. D. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.10.1789 · Cited by 66
Bruyère, O., Collette, J., Delmas, P. D., Rouillon, A., Roux, C., Seidel, L., Richy, F. F., & Reginster, J. (2003) · Maturitas · doi:10.1016/s0378-5122(03)00042-2 · Cited by 56
Uncertain Future of Trials in Osteoporosis
Kanis, J. A., Odén, A., Johnell, O., Caulin, F., Bone, H. G., Alexandre, J. M., Abadie, E., & Lekkerkerker, F. J. F. (2002) · Osteoporosis International · doi:10.1007/s001980200052 · Cited by 51
Biochemical Markers of Bone Turnover and Fracture Prediction
Hannon, R. A., & Eastell, R. (2003) · The Journal of the British Menopause Society · doi:10.1177/136218070300900106 · Cited by 41
Cited by
Russell, R. G. G., Watts, N. B., Ebetino, F. H., & Rogers, M. J. (2008) · Osteoporosis International · doi:10.1007/s00198-007-0540-8 · Cited by 1,411
for the IOF-IFCC Bone Marker Standards Working Group, Vasikaran, S., Eastell, R., Bruyère, O., Foldes, A. J., Garnero, P., Griesmacher, A., McClung, M., Morris, H. A., Silverman, S., et al. (2011) · Osteoporosis International · doi:10.1007/s00198-010-1501-1 · Cited by 1,212
Self-citationSambrook, P., & Cooper, C. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68891-0 · Cited by 1,165
Qaseem, A., Forciea, M. A., McLean, R. M., Denberg, T. D., & for the Clinical Guidelines Committee of the American College of Physicians* (2017) · Annals of Internal Medicine · doi:10.7326/m15-1361 · Cited by 676
Osteoporosis in Men: An Endocrine Society Clinical Practice Guideline
Watts, N. B., Adler, R. A., Bilezikian, J. P., Drake, M. T., Eastell, R., Orwoll, E. S., & Finkelstein, J. S. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3045 · Cited by 611
Metadata
- Authors
- Rosen, C. J., Hochberg, M. C., Bonnick, S. L., McClung, M., Miller, P., Broy, S., Kagan, R., Chen, E., Petruschke, R. A., Thompson, D. E., & de Papp, A. E.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-01-01
- Volume
- 20
- Issue
- 1
- Pages
- 141-151
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2009678900
- Cited by
- 345
- References
- 46
- FWCI
- 44.55
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.